Item 7.01 Regulation FD Disclosure.
On June 28, 2021, Taysha Gene Therapies, Inc. (the "Company") will host the
first day of a two-day virtual research and development day (the "R&D Day") for
analysts and investors to highlight the Company's research and development
progress, focused on advancement of its early- and late-stage investigational
programs. A copy of the presentation, dated June 28, 2021, that the Company
intends to use on the first day of the Company's R&D Day is furnished as Exhibit
99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 of this Current Report on 8-K (including
Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended. The information shall not be deemed incorporated by reference
into any other filing with the Securities and Exchange Commission made by the
Company, whether made before or after today's date, regardless of any general
incorporation language in such filing, except as shall be expressly set forth by
specific references in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Company presentation, dated June 28, 2021
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses